Abstract
We have investigated the value of both conventional and quantitative flow cytometry to detect minimal residual disease in 21 CLL patients in remission including bone marrow histology: eight in complete remission (CR), 11 in nodular partial remission (nPR) and two in PR. The techniques used were double immunostaining with CD5 and CD19 and quantitative estimation of the number of both antigens with standard microbeads. Reference values were established on normal peripheral blood and bone marrow controls. Patients were considered in ‘immunological’ remission when the percentage of CD5+ CD19+/total CD19+ cells was <25% in PB and <15% in bm. in six of the eight patients in cr, cll cells were still detectable by flow cytometry. only two patients, that underwent allogeneic bone marrow transplant, achieved immunological remission. cll samples showed significantly higher cd5 and lower cd19 antigen density than normal controls (P < 0.001). Persistence of residual disease was a predictor of time to progression. None of the two patients in immunological remission relapsed within a period of 13 and 33 months, whilst two of the six patients in CR with positive flow cytometry relapsed 3 and 6 months after achieving CR. This study demonstrates that flow cytometry contributes to increase the sensitivity of the clinicohematological criteria to detect residual malignant cells in CLL patients and may be useful to monitor disease status following treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cabezudo, E., Matutes, E., Ramrattan, M. et al. Analysis of residual disease in chronic lymphocytic leukemia by flow cytometry. Leukemia 11, 1909–1914 (1997). https://doi.org/10.1038/sj.leu.2400835
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2400835
Keywords
This article is cited by
-
Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments
Leukemia (2018)
-
Assessing minimal residual disease in chronic lymphocytic leukemia
Current Hematologic Malignancy Reports (2008)
-
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia
Leukemia (2007)
-
Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation
Leukemia (2004)
-
Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation
Leukemia (2002)